Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biondvax Pharma ADR (NQ: BVXV )

2.600 -0.050 (-1.89%)
Streaming Delayed Price Updated: 1:34 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biondvax Pharma ADR

< Previous 1 2 Next >
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Aiming to Capture Significant Market Share for Treatment and Prevention of COVID-19 Illness with Innovative Inhaled NanoAb
Via Investor Brand Network
Exposures COVID-19 Product Safety
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) to Present at BIO CEO & Investor Conference
Via Investor Brand Network
Exposures COVID-19
BiondVax Presenting at BIO CEO & Investor Conference
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
Research Links Two Natural Deposits to Onset of Macular Degeneration
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports Promising Prophylactic Results from Preclinical Proof-of-Concept NanoAb COVID-19 Study
Via Investor Brand Network
Exposures COVID-19
Toddlers, Infants Risk Severe Outcomes When Faced with Multiple Infections
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
Via Investor Brand Network
Exposures COVID-19 Product Safety
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
Scientists Discover Unknown T Cell Function That Can Help Fight Fungal Infections
Via Investor Brand Network
BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needs
Via Investor Brand Network
Exposures COVID-19
America Faces Shortage of Infectious Disease Experts
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Study Results Indicating Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus
Via Investor Brand Network
Exposures COVID-19
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Receives $57 Share Valuation on Potential of NanoAb Platform
Via Investor Brand Network
Exposures COVID-19
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Announces Participation in Upcoming Biotech Showcase
Via Investor Brand Network
Exposures COVID-19
BiondVax to Present at Biotech Showcase 2023
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Business Updates and Announces CEO’s Upcoming Speaking Engagements
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Letter to Shareholders
Via Investor Brand Network
Exposures COVID-19
BiondVax CEO Issues Letter to Shareholders
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well-Positioned to Bring Innovative Therapies to Market
Via Investor Brand Network
Exposures COVID-19
New Research Shows Brain Stimulation Improves Reading Ability of Macular Degeneration Patients
Via Investor Brand Network
BioMedNewsBreaks – Aegis Capital Corp. Acted as Sole Bookrunner on BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) $8M Underwritten Public Offering
Via Investor Brand Network
Aegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)
Via ACCESSWIRE
Experts Push for More Studies into Link Between Asthma, Female Sex Hormones
Via Investor Brand Network
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Closes $8M Underwritten Public Offering
Via Investor Brand Network
BiondVax Announces Closing of $8 Million Underwritten Public Offering
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Releases Pricing on Public Offering, Expects to Raid $8M
Via Investor Brand Network
BiondVax Announces Pricing of $8 Million Underwritten Public Offering
From BiondVax Pharmaceuticals Ltd.
Via Globe NewsWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.